• DOI:10.1182/BLOOD-2004-07-2942
Corpus ID: 7675860

AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.

@article{Choudhary2005AMLassociatedFK,
  title={AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.},
  author={C. Choudhary and J. Schwaeble and C. Brandts and L. Tickenbrock and B. Sargin and T. Kindler and T. Fischer and W. E. Berdel and C. M{\"u}ller-Tidow and H. Serve},
  journal={Blood},
  year={2005},
  volume={106 1},
  pages={
          265-73
        }
}

C. Choudhary, J. Schwaeble, +7 authors H. Serve

Published 2005

Medicine, Biology

Blood

Activating mutations of Flt3 are found in approximately one third of patients with acute myeloid leukemia (AML) and are an attractive drug target. Two classes of Flt3 mutations occur: internal tandem duplications (ITDs) in the juxtamembrane and point mutations in the tyrosine kinase domain (TKD). We and others have shown that Flt3-ITD induced aberrant signaling including strong activation of signal transducer and activator of transcription 5 (STAT5) and repression of CCAAT/estradiol-binding… CONTINUE READING

View on PubMed

bloodjournal.org

Save to Library

Create Alert

Cite

Launch Research Feed